Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA

February 17, 2026

26 min episode · 2 min read

Steve Austin,Lauren Martz

Episode

26 min

Read time

2 min

AI-Generated Summary

Published Mar 15, 2026

Key Takeaways

✓Oral SERD market size: Estrogen receptor-positive, HER2-negative breast cancer represents approximately 70% of all breast cancers, making oral SERDs a massive commercial opportunity. Two products already hold approval — Menarini's Elacestrant (2023) and Lilly's Imlunestrant (2025) — with 11 pipeline assets competing across second-line, first-line, and adjuvant treatment settings.
✓PROTAC milestone watch: Arvinas and Pfizer's vepdegestrant carries a June 2025 PDUFA date and could become the first approved PROTAC in any disease. Unlike indirect-mechanism oral SERDs, PROTACs directly label the estrogen receptor for degradation via E3 ligase linkage, potentially achieving deeper receptor knockdown in the second-line setting.
✓Differentiation strategy for crowded SERD field: With second-line indications becoming crowded, companies pursuing first-line and adjuvant settings — including Roche's giredestrant and AstraZeneca's camizestrant — gain competitive separation. Blood-brain-barrier penetration for brain metastasis coverage represents another concrete differentiation axis, with NRADI's SIRDU brain metastasis data expected in Q4.
✓FDA accelerated approval risk for orphan drugs: FDA issued a complete response letter to DISC Medicine based on biomarker clinical relevance skepticism, continuing a pattern of rejecting biomarker-based accelerated approvals in rare diseases. Investors and developers should treat accelerated approval pathways for orphan indications as materially less reliable under current FDA leadership, with Vinay Prasad directly involved in CDER decisions beyond his CBER role.
✓mRNA vaccine pipeline vulnerability: FDA's refusal to file Moderna's mRNA flu vaccine application creates a structural disincentive for mRNA influenza vaccine development. This is particularly consequential for pandemic preparedness: during an avian influenza outbreak, egg-based manufacturing faces supply constraints from poultry culling, making mRNA the only scalable rapid-response platform available.

What It Covers

BioCentury This Week episode 350 examines the oral SERD landscape, covering 11 pipeline assets competing for dominance in estrogen receptor-positive breast cancer, plus FDA's refusal to file Moderna's flu vaccine application and a complete response letter issued to DISC Medicine for an orphan disease therapy.

Key Questions Answered

•Oral SERD market size: Estrogen receptor-positive, HER2-negative breast cancer represents approximately 70% of all breast cancers, making oral SERDs a massive commercial opportunity. Two products already hold approval — Menarini's Elacestrant (2023) and Lilly's Imlunestrant (2025) — with 11 pipeline assets competing across second-line, first-line, and adjuvant treatment settings.
•PROTAC milestone watch: Arvinas and Pfizer's vepdegestrant carries a June 2025 PDUFA date and could become the first approved PROTAC in any disease. Unlike indirect-mechanism oral SERDs, PROTACs directly label the estrogen receptor for degradation via E3 ligase linkage, potentially achieving deeper receptor knockdown in the second-line setting.
•Differentiation strategy for crowded SERD field: With second-line indications becoming crowded, companies pursuing first-line and adjuvant settings — including Roche's giredestrant and AstraZeneca's camizestrant — gain competitive separation. Blood-brain-barrier penetration for brain metastasis coverage represents another concrete differentiation axis, with NRADI's SIRDU brain metastasis data expected in Q4.
•FDA accelerated approval risk for orphan drugs: FDA issued a complete response letter to DISC Medicine based on biomarker clinical relevance skepticism, continuing a pattern of rejecting biomarker-based accelerated approvals in rare diseases. Investors and developers should treat accelerated approval pathways for orphan indications as materially less reliable under current FDA leadership, with Vinay Prasad directly involved in CDER decisions beyond his CBER role.
•mRNA vaccine pipeline vulnerability: FDA's refusal to file Moderna's mRNA flu vaccine application creates a structural disincentive for mRNA influenza vaccine development. This is particularly consequential for pandemic preparedness: during an avian influenza outbreak, egg-based manufacturing faces supply constraints from poultry culling, making mRNA the only scalable rapid-response platform available.

Notable Moment

BioCentury's Washington editor, who has covered FDA for over 30 years, publicly called on CEOs of major pharmaceutical companies to demand Vinay Prasad's removal from FDA — a step he described as unprecedented in his career, citing staff harassment complaints, routine override of experienced scientists, and unpredictable regulatory decisions.

Know someone who'd find this useful?